Aspen Pharmacare (APNHY)
(Delayed Data from OTC)
$11.29 USD
0.00 (0.00%)
Updated Apr 25, 2024 01:10 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Aspen Pharmacare falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 2,296 | 2,540 | 2,462 | 2,489 | 2,740 |
Cost Of Goods | 1,228 | 1,336 | 1,303 | 1,244 | 1,352 |
Gross Profit | 1,068 | 1,205 | 1,160 | 1,245 | 1,389 |
Selling & Adminstrative & Depr. & Amort Expenses | 627 | 634 | 699 | 790 | 1,050 |
Income After Depreciation & Amortization | 441 | 571 | 461 | 455 | 339 |
Non-Operating Income | 30 | 7 | 9 | 10 | 31 |
Interest Expense | 101 | 42 | 80 | 104 | 175 |
Pretax Income | 370 | 535 | 390 | 361 | 195 |
Income Taxes | 75 | 108 | 78 | 64 | 55 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 295 | 427 | 313 | 297 | 141 |
Extras & Discontinued Operations | 0 | 0 | 1 | 3 | 315 |
Net Income (GAAP) | 295 | 427 | 313 | 300 | 456 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 542 | 683 | 569 | 558 | 429 |
Depreciation & Amortization (Cash Flow) | 101 | 113 | 108 | 103 | 90 |
Income After Depreciation & Amortization | 441 | 571 | 461 | 455 | 339 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 444.20 | 453.00 | 456.50 | 456.50 | 456.50 |
Diluted EPS Before Non-Recurring Items | 0.84 | 1.07 | 0.79 | 0.82 | 1.00 |
Diluted Net EPS (GAAP) | 0.66 | 0.94 | 0.69 | 0.66 | 1.00 |
Fiscal Year end for Aspen Pharmacare falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |